Sugi Predict

Sugi Predict / Compounds / SCHEMBL628865

SCHEMBL628865

SCHEMBL628865

Cc1cc(C(=O)O)ccc1NC(=O)OC(C)(C)C

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 2/20 0.46
▸ ATM Q13315 2/20 0.46
▸ RAB9A P51151 2/20 0.46
▸ JAK2 O60674 1/20 0.46
▸ HTT P42858 1/20 0.46
▸ NPSR1 Q6W5P4 1/20 0.46
▸ SMN1; SMN2 Q16637 1/20 0.45
▸ KDM4E B2RXH2 2/20 0.45
▸ ALDH1A1 P00352 2/20 0.45
▸ LMNA P02545 1/20 0.45
▸ NPC1 O15118 2/20 0.44
▸ ABCC9 O60706 2/20 0.44
▸ ABCC8 Q09428 2/20 0.44
▸ KCNJ11 Q14654 2/20 0.44
▸ KCNJ8 Q15842 2/20 0.44
▸ L3MBTL1 Q9Y468 1/20 0.44
▸ CYP17A1 P05093 1/20 0.44
▸ TAS1R3 Q7RTX0 1/20 0.43
▸ TAS1R1 Q7RTX1 1/20 0.43
▸ TAS1R2 Q8TE23 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30587156 1.00 MAPT (0.46) MAPTATMRAB9AJAK2HTT
SCHEMBL8509027 0.92 CISD2 (0.42) MAPTATMRAB9AJAK2HTT
SCHEMBL2283371 0.88 PPARG (0.51) MAPTATMRAB9ASMN1; SMN2KDM4E
SCHEMBL3256083 0.88 NPC1 (0.54) MAPTATMSMN1; SMN2KDM4EALDH1A1
SCHEMBL11959276 0.87 LCK (0.49) MAPTATMRAB9ASMN1; SMN2KDM4E
SCHEMBL4927166 0.85 KDM5A (0.50) MAPTHTTKDM4ENPC1ABCC9
SCHEMBL5151365 0.84 ABCC9 (0.44) SMN1; SMN2LMNAABCC9ABCC8KCNJ11
SCHEMBL8297312 0.84 SMN1; SMN2 (0.63) MAPTATMRAB9AHTTSMN1; SMN2
SCHEMBL16399332 0.84 MAPT (0.45) MAPTRAB9AHTTSMN1; SMN2KDM4E
SCHEMBL4851444 0.84 MAPT (0.45) MAPTATMHTTKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230312491-A1 N-SUBSTITUTED 4-(5-PHENYL-1,3,4-OXADIAZOL-2-YL)ANILINE FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION HOFFMANN-LA ROCHE INC. (US) 2023-10-05 — — US disclosed
CN-116457353-A N-substituted 4- (5-phenyl-1, 3, 4-oxadiazol-2-yl) anilines for the treatment and prophylaxis of hepatitis b virus infections 豪夫迈·罗氏有限公司 2023-07-18 — — CN disclosed
US-20230183226-A1 AKT3 MODULATORS Georgiamune Inc. 2023-06-15 — — US disclosed
WO-2023081854-A1 AKT3 MODULATORS GEORGIAMUNE LLC (US) 2023-05-11 — — WO disclosed
WO-2022112139-A1 N-SUBSTITUTED 4-(5-PHENYL-1,3,4-OXADIAZOL-2-YL)ANILINE FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION F. HOFFMANN-LA ROCHE AG (CH) 2022-06-02 — — WO disclosed
WO-2021226519-A1 AKT3 MODULATORS GEORGIAMUNE LLC (US) 2021-11-11 — — WO disclosed
EP-3586838-B1 AMIDE DERIVATIVE DAIICHI SANKYO CO LTD (JP) 2021-10-27 — — EP disclosed
US-10925848-B2 Amide derivative DAIICHI SANKYO COMPANY, LIMITED (JP) 2021-02-23 — — US disclosed
CN-110325184-A Amide derivatives 第一三共株式会社 2019-10-11 — — CN disclosed
WO-2018136935-A1 2-ARYLSULFONAMIDO-N-ARYLACETAMIDE DERIVATIZED STAT3 INHIBITORS UNIVERSITY OF HAWAII (US) 2018-07-26 — — WO disclosed
CN-1264385-A Novel 2-(iminomethyl) amino-phenyl derivatives, preparation, application as medicines and compositions containing same SOD CONSEILS RECH APPLIC (FR) 2000-08-23 — — CN disclosed
EP-0986384-A1 INHIBITORS OF PROTEIN ISOPRENYL TRANSFERASES UNIVERSITY OF PITTSBURGH (US) 2000-03-22 — — EP disclosed
US-5965539-A PEPTIDOMIMETICS; ANTI-CANCER DRUGS UNIVERISTY OF PITTSBURGH (US) 1999-10-12 — — US disclosed
EP-0794789-A4 INHIBITORS OF PRENYL TRANSFERASES UNIV PITTSBURGH (US) 1999-05-26 — — EP disclosed
WO-1998050031-A1 INHIBITORS OF PROTEIN ISOPRENYL TRANSFERASES UNIVERSITY OF PITTSBURGH (US) 1998-11-12 — — WO disclosed
WO-1998050030-A1 INHIBITORS OF PROTEIN ISOPRENYL TRANSFERASES UNIVERSITY OF PITTSBURGH (US) 1998-11-12 — — WO disclosed
WO-1998050029-A1 INHIBITORS OF PROTEIN ISOPRENYL TRANSFERASES UNIVERSITY OF PITTSBURGH (US) 1998-11-12 — — WO disclosed
US-5834434-A PEPTIDOMIMETICS UNIVERSITY OF PITTSBURGH (US) 1998-11-10 — — US disclosed
EP-0794789-A1 INHIBITORS OF PRENYL TRANSFERASES UNIVERSITY OF PITTSBURGH (US) 1997-09-17 — — EP disclosed
WO-1996021456-A1 INHIBITORS OF PRENYL TRANSFERASES UNIVERSITY OF PITTSBURGH (US) 1996-07-18 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230183226-A1 AKT3 MODULATORS AKT3, AKT2, MTOR MAPT 3999/4885ATM 310/4885RAB9A 1375/4885
US-10925848-B2 Amide derivative IDO1, IDO2, TPH1 MAPT 4144/4885ATM 4420/4885RAB9A 2356/4885
US-20230312491-A1 N-SUBSTITUTED 4-(5-PHENYL-1,3,4-OXADIAZOL-2-YL)ANILINE FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION SLC10A1, HAVCR2, CYP4B1 MAPT 4059/4885ATM 4810/4885RAB9A 2865/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.